MedTrace Logo

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

NCT04718584 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2021-01-22

No results posted yet for this study

Summary

This is a single-arm,open, multicenter, phase II clinical study of the efficacy and safety of human anti-PD-L1 monoclonal antibody Injection (LDP) in the treatment of urinary and male genital tumors.

Conditions

Interventions

DRUG

Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)

All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Dragonboat Biopharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Dingwei Ye · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2022-11-30
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04718584 on ClinicalTrials.gov